In8Bio (INAB) Change in Account Payables (2020 - 2026)
In8Bio (INAB) posted Change in Account Payables of $140000.0 for Q1 2026, up 33.33% sequentially from $105000.0 in Q4 2025, and down 24.73% YoY from $186000.0 in Q1 2025.
In8Bio (INAB) Change in Account Payables (2020 - 2026) Analysis & Trends
In8Bio has reported Change in Account Payables for 7 years, with the latest figure at $140000.0 in Q1 2026.
- Quarterly Change in Account Payables fell 24.73% year-over-year to $140000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$126000.0 (up 84.96% YoY) and the FY2025 annual result came in at -$80000.0, up 85.05% from the prior year.
- Change in Account Payables rose to $140000.0 in Q1 2026 per INAB's latest filing, from $105000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $800000.0 in Q4 2022 and troughed at -$1.0 million in Q1 2023.
- A 5-year average of $3176.5 and a median of $105000.0 in 2025 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables soared 321.61% in 2022, then slumped 775.86% in 2025.
- Over 5 years, Change in Account Payables stood at $800000.0 in 2022, then slumped by 75.0% to $200000.0 in 2023, then sank by 473.0% to -$746000.0 in 2024, then surged by 114.08% to $105000.0 in 2025, then jumped by 33.33% to $140000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $140000.0, $105000.0, and -$175000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | -5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,000.00 |
| Jun 30, 2026 | -5,000.00 |
| Mar 31, 2026 | 140,000.00 |
| Mar 31, 2026 | 140,000.00 |
| Dec 31, 2025 | 105,000.00 |
| Dec 31, 2025 | 105,000.00 |
| Sep 30, 2025 | -175,000.00 |
| Sep 30, 2025 | -175,000.00 |
| Jun 30, 2025 | -196,000.00 |
| Jun 30, 2025 | -196,000.00 |
| Mar 31, 2025 | 186,000.00 |
| Mar 31, 2025 | 186,000.00 |
| Dec 31, 2024 | -746,000.00 |
| Dec 31, 2024 | -746,000.00 |
| Sep 30, 2024 | -307,000.00 |
| Sep 30, 2024 | -307,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Mar 31, 2024 | 489,000.00 |
| Mar 31, 2024 | 489,000.00 |